CFO Moves this week include:
| KMG Chemicals, Inc. | ImmunoGen, Inc. | MELA Sciences, Inc. |
| Eleven Biotherapeutics | Techne Corporation | Tessera Technologies, Inc. |
| PICS Auditing, LLC | SoFi (Social Finance, Inc.) | Activu Corporation |
| Sheppard Mullin Richter & Hampton LLP | Cellular Biomedicine Group Inc. |
Would you like to receive our weekly CFO Moves directly in your email? Click the SIGN ME UP! button on the right of the blog page.
Should you have any CFO Moves to report, please email us.
CFO Moves is published by Samuel Dergel (Executive Search Consultant and CFO & Financial Executive Search Specialist with Stanton Chase International). Samuel can be reached by email at s.dergel@stantonchase.com or by phone at +1 (415) 738-2070.
+ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + +
KMG Chemicals, Inc. (NYSE: KMG) announced that Malinda Passmore has been named vice president and chief financial officer. Passmore will join KMG on January 27, 2014. Most recently, Passmore was chief financial officer of Country Fresh. Prior to her position as CFO of Country Fresh, Passmore was senior vice president finance for Archipelago Learning.
ImmunoGen, Inc. (NASDAQ: IMGN) announced the appointment of David Johnston as Executive Vice President and Chief Financial Officer. Mr. Johnston joins ImmunoGen from AVEO Pharmaceuticals Inc., where he was the CFO. Prior to joining AVEO in 2007, Mr. Johnston was Senior Vice President of Finance, Corporate Planning and Analysis at Genzyme Corporation and, before that, the VP Finance and CFO of Genzyme Biosurgery.
MELA Sciences, Inc. (NASDAQ: MELA) announced the resignation of Richard I. Steinhart, SVP Finance and Chief Financial Officer. Mr. Steinhart has served as MELA’s CFO since 2006.
Eleven Biotherapeutics announced the appointment of Gregory D. Perry as Chief Financial and Business Officer, and Daniel S. Lynch as Chairman of the company’s board of directors. Prior to joining Eleven Biotherapeutics, Gregory D. Perry served as Interim Chief Financial Officer of InVivo Therapeutics (NVIV). Prior to InVivo, Mr. Perry was Executive Vice President and Chief Financial Officer of Immunogen, Inc. (IMGN) from 2009 to 2013, where he led the company’s strategic transition from a platform technology company to a product development company. Prior to Immunogen, Mr. Perry served as Chief Financial Officer (CFO) of Elixir Pharmaceuticals. He served as CFO of Domantis, Ltd. until its acquisition by GlaxoSmithKline in 2006, and as CFO of Transkaryotic Therapies, Inc. (TKT) until its acquisition by Shire plc in 2005. Before joining Transkaryotic Therapies in 2003, Mr. Perry served in financial management positions of increasing responsibility at PerkinElmer, Inc., Honeywell and GE’s European medical systems business unit. Daniel S. Lynch spent nearly five years at ImClone Systems, serving as chief executive officer and chief financial officer. As CFO, Dan led negotiations to form the major partnership between ImClone and Bristol-Myers Squibb. Earlier in his career, he served in various financial positions at Bristol-Myers Squibb over a 15-year tenure. He served on the board of directors and the audit committee of U.S. Oncology, Inc. for five years until December, 2010, when it was acquired by McKesson. More recently Dan was Executive Chairman of the board for Avila Therapeutics and Stromedix. In addition to Eleven Biotherapeutics, Dan is currently a member of the board of directors for BIND Therapeutics, bluebird bio, Blueprint Medicines, Nimbus Discovery and RaNA Therapeutics.
Techne Corporation (NASDAQ: TECH) announced that Gregory J. Melsen will resign from his position as Chief Financial Officer, effective February 3, 2014, to pursue other opportunities. Mr. Melsen has served as Techne’s Chief Financial Officer since 2004.
Tessera Technologies, Inc. (NASDAQ: TSRA) announced the appointment of Robert J. Andersen as the Company’s executive vice president and chief financial officer (CFO). John Allen, who had served as the Company’s acting CFO since June 2013, returned to his prior position as the Company’s senior vice president and corporate controller. Andersen most recently served from June 2011 to July 2013 as the CFO and executive vice president of G2 Holdings Corp. d/b/a Components Direct, which was acquired by Avnet, Inc. in April 2013. From September 2008 to June 2011, Andersen served first as vice president of finance and then as CFO at Phoenix Technologies Ltd., and was acquired by an affiliate of Marlin Equity Partners in November 2010. Prior to his time at Phoenix Technologies, Andersen served in various senior financial roles at Wind River Systems, Inc., and NextOffice, Inc.
PICS Auditing, LLC announced that Peter B. Harker has joined the company as Chief Financial Officer. Peter served as CFO at QTC (acquired by Lockheed Martin) for four years. Prior to QTC, Mr. Harker served as CFO at LogicalApps (acquired by Oracle), Medidata Solutions, and Optum Software.
SoFi (Social Finance, Inc.) announced its Chief Financial Officer Nino Fanlo is expanding his role at the company to take on the additional responsibilities of Chief Operating Officer. Nino Fanlo joined SoFi in June of 2012 as CFO. Fanlo was formerly the Chief Executive Officer of KKR Financial and Executive Vice President and Treasurer of Wells Fargo.
Activu Corporation announced the appointment of Richard Aguinaldo as the company’s new Chief Financial Officer. Most recently, Aguinaldo was a Finance Director at ShoreTel, Inc. Prior to ShoreTel, he was the VP, Finance and Controller for M5 Networks, Inc., before it was acquired by ShoreTel. Aguinaldo has also previously held finance positions at Metropolitan Telecommunications (Mettel), Espernet.com and RCG Information Technology.
Sheppard Mullin Richter & Hampton LLP announced that Ted Tinson has joined as Chief Operating Officer. Tinson joins from Dentons, where he served as the Chief Financial Officer for, and also carried out many of the COO functions, Dentons’ U.S. and Asia-Pacific regions. Tinson replaces Sheppard Mullin’s executive director Bob Zuber, who is retiring after 17 years with the firm.
Cellular Biomedicine Group Inc. (OTC: CBMG) announced the appointment of Bizuo (Tony) Liu as Chief Financial Officer and Board Secretary and the election of Nadir Patel as Independent Director, Chairman of the Audit Committee of the board of directors of CBMG. Most recently Mr. Liu served as Corporate Vice President at Alibaba Group, responsible for Alibaba’s overseas investments. He was also Chief Financial Officer for HiChina, a subsidiary of Alibaba. Prior to joining Alibaba, Mr. Liu spent 19 years at Microsoft Corporation where he served in a variety of finance leadership roles. Prior to becoming CBMG’s Chief Financial Officer, Mr. Liu had been serving as an Independent Director and Chairman of the Audit Committee for CBMG since March 2013. CBMG’s current Chief Financial Officer and Board Secretary, Andrew Chan, will move to the exciting new role of Senior Vice President of Corporate Business Development.Mr. Patel is currently Assistant Deputy Minister, Corporate Planning, Finance and Information Technology, and Chief Financial Officer for Canada’s Department of Foreign Affairs, Trade and Development. Previously Mr. Patel served as Canada’s Consul General in Shanghai, promoting trade and investment between Canada and China. Mr. Patel also serves on the Board of Governors of the International Development Research Centre (and on its Audit and Finance Committee), as well as the Ottawa Advisory Board of Wilfrid Laurier University’s School of Business and Economics.
Leave a Reply